EIB grants EUR 150 million loan to Alfasigma for rare-disease and specialty-care R&D

Mechanism

EIB direct corporate lending: a EUR 150 million facility to a single private pharmaceutical group, earmarked for a defined three-year R&D programme rather than general working capital. This is standard EIB "innovation and skills" pillar financing — preferential-rate, EU-policy-bank debt substituting for market financing, which is why GTA logs it as a state-loan intervention even though no state aid notification/clearance is involved (EIB lending sits outside EU State Aid rules).

Severity is set low (2) given the modest absolute size relative to EIB's lending book and the narrow single-company beneficiary, consistent with comparable EIB/EIF single-recipient loans already in the register (e.g. the Portugal EIF-Fomento guarantee, severity 2).

Downstream implications

• Adds to the EIB's growing book of "competitiveness and innovation"

lending to EU pharma/life-sciences firms, part of the broader EU industrial-policy response to US IRA-style subsidy competition.

• No trade-control or market-access effect; pure financing support.

Open questions

• Whether Alfasigma draws further EIB tranches for the same 2025-2027

programme (would be an amendment, not a new action).